Device Technologies Australia Pty Ltd

Device Technologies Australia Pty Ltd, headquartered in Sydney, provides a wide array of medical devices and supplies that enhance patient care across various healthcare sectors in Australia and New Zealand. Device Technologies Australia Pty Ltd was established in 1992 in Sydney, Australia, specializing in the supply of medical devices to healthcare professionals. The company underwent a Secondary Buyout in November 2018 when Navis Capital Partners acquired it from Pemba Capital Partners for AUD 700 million. The current CEO is Ed Maisen, with Mick Trevaskis playing a significant role in the leadership team.

Founder Peter Ord has a history of entrepreneurial ventures in the medical industry. Device Technologies focuses on a comprehensive range of medical devices aimed at improving patient outcomes. Their offerings cover specialties such as cardiothoracic surgery, critical care, gastroenterology, infection prevention, and orthopedics, providing healthcare professionals with high-quality technology for consult rooms and operating theatres. The company serves both public and private healthcare facilities across Australia and New Zealand, continuously updating their product portfolio with the latest medical innovations.

In the most recent year, 2018, Device Technologies reported a revenue of AUD 323,717,630. 20 and an EBITDA of AUD 35,952,112. 80. The company operates on a B2B model, supplying large orders of medical devices directly to healthcare institutions, which enables consistent revenue generation through contractual agreements with hospitals and healthcare providers.

Following the acquisition by Navis Capital Partners in November 2018, Device Technologies is expected to strategically enhance its product offerings and expand into new markets. The company is focusing on designing and launching new medical devices aimed at improving patient care outcomes. Specific geographical expansion into other regions is being planned, although exact timelines and target markets have not been disclosed. The funding from the recent acquisition is anticipated to support these initiatives, enhancing their capabilities to deliver advanced medical solutions.